Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System

Inclusion Criteria: * Subject is willing to sign and date the consent form. * Subject is indicated for a Reveal device within the existing market approved indications * Phase I (initial 30 subjects): Any indication for a Reveal LINQ Device * Phase II (after the initial 30 subjects): Subject has atrial fibrillation and is indicated for and identified as an AF pre-ablation candidate\* \*Note: Atrial fibrillation must be documented in the subject's medical history. * Subject has a life expectancy of 18 months or more. * Subject is willing and able to set up and utilize MyCareLink® home monitor and be remotely monitored (i.e., Medtronic CareLink® Network) * Subjects who are female of childbearing potential (last menses less than 1 year prior to enrolment) must: * have a negative pregnancy test at enrollment. * not be breastfeeding. * either be surgically sterile, postmenopausal (cessation of menses for at least 1 year), or agree to use a medically accepted, highly effective method of contraception during the entire duration of the study. Exclusion Criteria: * Subject has an active implanted cardiac medical device (e.g., IPG, ICD, CRT, etc). * Subject is unwilling or unable to comply with the study procedures * Subject is legally incapacitated and unable to provide written informed consent. * Any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological diagnosis) * Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from Medtronic study manager. * Local law prohibits participation (e.g., minor status as specified by local law)